6533b7d6fe1ef96bd126676e

RESEARCH PRODUCT

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

Mariano BlascoAntonio Hernández-mijaresXavier PintóÁNgel DíazJuan F. AscasoJesús MillánTeresa MantillaÁNgel BreaJuan Pedro-botet

subject

medicine.medical_specialtyApolipoprotein BPhysical exercisechemistry.chemical_compoundFenofibrateRisk FactorsWeight lossInternal medicinemedicineHumansTriglyceridesDyslipidemiasHypolipidemic AgentsGeneral Environmental ScienceFenofibratebiologybusiness.industryCholesterolGeneral Engineeringnutritional and metabolic diseasesAtherosclerosismedicine.diseaseLipidsResidual riskCholesterolEndocrinologychemistryCardiovascular Diseasesbiology.proteinGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessDyslipidemiamedicine.drugLipoprotein

description

Abstract There is no doubt about the relationship between LDL-C and cardiovascular risk, as well as about the benefits of statin treatment. Once the objective of LDL-C has been achieved, the evidences that demonstrate the persistence of a high cardiovascular risk, a concept called residual risk, are notable. The residual risk of lipid origin is based on atherogenic dyslipidemia, characterised by an increase in triglycerides and triglyceride-rich lipoproteins, a decrease in HDL-C and qualitative alterations in LDL particles. The most commonly used measures to identify this dyslipidemia are based on the determination of total cholesterol, triglycerides, HDL, non-HDL cholesterol and remaining cholesterol, as well as apolipoprotein B100 and lipoprotein(a) in certain cases. The treatment of atherogenic dyslipidemia is based on weight loss and physical exercise. Regarding pharmacological treatment, we have no evidence of cardiovascular benefit with drugs aimed at lowering triglycerides and HDL-C, fenofibrate seems to be effective in situations of atherogenic dyslipidemia.

yearjournalcountryeditionlanguage
2019-03-01Clínica e Investigación en Arteriosclerosis (English Edition)
https://doi.org/10.1016/j.artere.2019.02.002